Meeting Banner
Abstract #0267

Whole-gland MRI-guided transurethral ultrasound ablation of low-risk prostate cancer: preliminary results from a multi-center phase I clinical trial

Matthias C. Roethke 1 , Mathieu Burtnyk 2 , Timur H. Kuru 3 , Maya Wolf 1 , Gencay Hatiboglu 3 , Michele Billia 4 , Cesare Romagnoli 5 , Sascha Pahernik 3 , Joseph Chin 4 , and Heinz-Peter Schlemmer 1

1 Radiology, German Cancer Research Center (DKFZ), Heidelberg, Germany, 2 Profound Medical Inc., Toronto, Ontario, Canada, 3 Urology, University Hospital Heidelberg, Germany, 4 Urology, Western University UWO, London Health Sciences Center, London Victoria Hospital, Ontario, Canada, 5 Radiology, Western University UWO, London Health Sciences Center, London Victoria Hospital, Ontario, Canada

MRI-guided transurethral ultrasound ablation is a novel minimally-invasive treatment for localised prostate cancer, where a volume of thermal ablation is generated and shaped precisely to the prostate using MR-thermometry feedback control. A phase I safety and feasibility clinical trial was initiated, with 16 patients treated to-date and no cases of urinary incontinence or rectal injury. Median treatment time and prostate volume were 29min and 45ml. Spatial control of the ablation volume was -0.11.4mm (+0.5/-1.2ml), with good correlation to the non-perfused volume on post-treatment CE-MRI. At 1-month, median PSA reduced by 87% to 0.7ng/ml, with the nadir expected by 6 months.

This abstract and the presentation materials are available to members only; a login is required.

Join Here